Familial Renal Cancer: Molecular Genetics and Surgical Management
Figure 3
Alterations in the intracellular tyrosine kinase domain of the MET proto-oncogene are found in patients with HPRC. These mutations result in the activation of the MET pathway. (From Linehan et al. [10], with permission.)
